Basic Description

Product Name	Recombinant BTK Antibody - Primary antibody, specific to BTK, Rabbit IgG
Synonyms	Agammaglobulinaemia tyrosine kinase antibody; AGMX 1 antibody; AGMX1 antibody; AT antibody; ATK antibody; B cell progenitor kinase antibody; B-cell progenitor kinase antibody; BPK antibody; Bruton agammaglobulinemia tyrosine kinase antibody; Bruton tyrosi
Specifications & Purity	ExactAb™, Validated, Recombinant, 0.7 mg/mL
Host species	Rabbit
Specificity	BTK
Immunogen	Recombinant protein of human BTK (AA 382-659).
Positive Control	WB: K562, THP-1, Ramos and Raji cell lysates. IHC: Human tonsil tissue
Conjugation	Unconjugated
Grade	ExactAb™, Recombinant, Validated
Product Description	Rabbit anti Human BTK Antibody, Recombinant, could be used for WB, IHC and so on. Application: WB: 1/500-1/1000 IHC: 1/50-1/100 Protein Function Plays a crucial role in B-cell ontogeny. Transiently phosphorylates GTF2I on tyrosine residues in response to B-cell receptor cross-linking. Required for the formation of functional ARID3A DNA-binding complexes.

Product Properties

Isotype	Rabbit IgG
SDS-PAGE	150 kDa
Purification Method	Antigen affinity purified
Form	Liquid
Concentration	0.7 mg/mL
Storage Temp	Store at -20°C,Avoid repeated freezing and thawing
Shipped In	Ice chest + Ice pads
Stability And Storage	Store at 4°C short term (1-2 weeks). Store at -20°C long term (24 months). Upon delivery aliquot. Avoid freeze/thaw cycle.

Images

Recombinant BTK Antibody (Ab091828) - Western Blot
All lanes: Recombinant BTK Antibody (Ab091828) at 1/1000 dilution
Samples: Lysates at 20 µg per lane
Secondary: Goat Anti-Rabbit IgG H&L (HRP) (Ab170144) at 1/20000 dilution

Predicted band size: 76 kDa
Observed band size: 73 kDa
Exposure time: 20.9 s

Recombinant BTK Antibody (Ab091828) - IHC
Immunohistochemistry analysis of paraffin-embedded Human tonsil using Recombinant BTK Antibody (Ab091828). High-pressure and temperature Sodium Citrate pH 6.0 was used for antigen retrieval.

Associated Targets

BTK Tclin Tyrosine-protein kinase BTK 0 Activities

Discover Target: BTK

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Application

Application	Dilution info
WB	1/500-1/1000
IHC	1/50 - 1/100

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

2 results found

Lot Number	Certificate Type	Date	Item
ZJ24F0102664	Certificate of Analysis	Jan 30, 2024	Ab091828
ZJ24F0102663	Certificate of Analysis	Jan 30, 2024	Ab091828

References

1. Marcotte DJ, Liu YT, Arduini RM, Hession CA, Miatkowski K, Wildes CP, Cullen PF, Hong V, Hopkins BT, Mertsching E et al.. (2010) Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases.. Protein Sci, 19 (3): (429-39). [PMID:20052711]
2. Soth M, Hermann JC, Yee C, Alam M, Barnett JW, Berry P, Browner MF, Frank K, Frauchiger S, Harris S et al.. (2013) 3-Amido pyrrolopyrazine JAK kinase inhibitors: development of a JAK3 vs JAK1 selective inhibitor and evaluation in cellular and in vivo models.. J Med Chem, 56 (1): (345-56). [PMID:23214979]
3. Kopecky DJ, Hao X, Chen Y, Fu J, Jiao X, Jaen JC, Cardozo MG, Liu J, Wang Z, Walker NP et al.. (2008) Identification and optimization of N3,N6-diaryl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamines as a novel class of ACK1 inhibitors.. Bioorg Med Chem Lett, 18 (24): (6352-6). [PMID:18993068]
4. Zhou W, Ercan D, Chen L, Yun CH, Li D, Capelletti M, Cortot AB, Chirieac L, Iacob RE, Padera R et al.. (2009) Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.. Nature, 462 (7276): (1070-4). [PMID:20033049]
5. Adrián FJ, Ding Q, Sim T, Velentza A, Sloan C, Liu Y, Zhang G, Hur W, Ding S, Manley P et al.. (2006) Allosteric inhibitors of Bcr-abl-dependent cell proliferation.. Nat Chem Biol, 2 (2): (95-102). [PMID:16415863]
6. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C et al.. (2007) Patterns of somatic mutation in human cancer genomes.. Nature, 446 (7132): (153-8). [PMID:17344846]
7. Remsing Rix LL, Rix U, Colinge J, Hantschel O, Bennett KL, Stranzl T, Müller A, Baumgartner C, Valent P, Augustin M et al.. (2009) Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.. Leukemia, 23 (3): (477-85). [PMID:19039322]
8. Ballou LM, Selinger ES, Choi JY, Drueckhammer DG, Lin RZ. (2007) Inhibition of mammalian target of rapamycin signaling by 2-(morpholin-1-yl)pyrimido[2,1-alpha]isoquinolin-4-one.. J Biol Chem, 282 (33): (24463-70). [PMID:17562705]
9. Devadas B, Selness SR, Xing L, Madsen HM, Marrufo LD, Shieh H, Messing DM, Yang JZ, Morgan HM, Anderson GD et al.. (2011) Substituted N-aryl-6-pyrimidinones: a new class of potent, selective, and orally active p38 MAP kinase inhibitors.. Bioorg Med Chem Lett, 21 (13): (3856-60). [PMID:21620699]
10. Guagnano V, Furet P, Spanka C, Bordas V, Le Douget M, Stamm C, Brueggen J, Jensen MR, Schnell C, Schmid H et al.. (2011) Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase.. J Med Chem, 54 (20): (7066-83). [PMID:21936542]
11. Apsel B, Blair JA, Gonzalez B, Nazif TM, Feldman ME, Aizenstein B, Hoffman R, Williams RL, Shokat KM, Knight ZA. (2008) Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.. Nat Chem Biol, 4 (11): (691-9). [PMID:18849971]
12. Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B, Karaman MW, Pratz KW, Pallares G, Chao Q et al.. (2009) AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).. Blood, 114 (14): (2984-92). [PMID:19654408]
13. Di Paolo JA, Huang T, Balazs M, Barbosa J, Barck KH, Bravo BJ, Carano RA, Darrow J, Davies DR, DeForge LE et al.. (2011) Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis.. Nat Chem Biol, 7 (1): (41-50). [PMID:21113169]
14. Manfredi MG, Ecsedy JA, Meetze KA, Balani SK, Burenkova O, Chen W, Galvin KM, Hoar KM, Huck JJ, LeRoy PJ et al.. (2007) Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase.. Proc Natl Acad Sci USA, 104 (10): (4106-11). [PMID:17360485]
15. Hall MD, Salam NK, Hellawell JL, Fales HM, Kensler CB, Ludwig JA, Szakács G, Hibbs DE, Gottesman MM. (2009) Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.. J Med Chem, 52 (10): (3191-204). [PMID:19397322]
16. Lafleur K, Huang D, Zhou T, Caflisch A, Nevado C. (2009) Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4).. J Med Chem, 52 (20): (6433-46). [PMID:19788238]
17. Li X, Zuo Y, Tang G, Wang Y, Zhou Y, Wang X, Guo T, Xia M, Ding N, Pan Z. (2014) Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity.. J Med Chem, 57 (12): (5112-28). [PMID:24915291]
18. Hudkins RL, Becknell NC, Zulli AL, Underiner TL, Angeles TS, Aimone LD, Albom MS, Chang H, Miknyoczki SJ, Hunter K et al.. (2012) Synthesis and biological profile of the pan-vascular endothelial growth factor receptor/tyrosine kinase with immunoglobulin and epidermal growth factor-like homology domains 2 (VEGF-R/TIE-2) inhibitor 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (CEP-11981): a novel oncology therapeutic agent.. J Med Chem, 55 (2): (903-13). [PMID:22148921]
19. Okuzumi T, Fiedler D, Zhang C, Gray DC, Aizenstein B, Hoffman R, Shokat KM. (2009) Inhibitor hijacking of Akt activation.. Nat Chem Biol, 5 (7): (484-93). [PMID:19465931]
20. Xu D, Kim Y, Postelnek J, Vu MD, Hu DQ, Liao C, Bradshaw M, Hsu J, Zhang J, Pashine A et al.. (2012) RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents.. J Pharmacol Exp Ther, 341 (1): (90-103). [PMID:22228807]
21. Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR et al.. (2016) Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.. N Engl J Med, 374 (4): (323-32). [PMID:26641137]
22. Doyle SL, Jefferies CA, Feighery C, O'Neill LA. (2007) Signaling by Toll-like receptors 8 and 9 requires Bruton's tyrosine kinase.. J Biol Chem, 282 (51): (36953-60). [PMID:17932028]
23. Horwood NJ, Page TH, McDaid JP, Palmer CD, Campbell J, Mahon T, Brennan FM, Webster D, Foxwell BM. (2006) Bruton's tyrosine kinase is required for TLR2 and TLR4-induced TNF, but not IL-6, production.. J Immunol, 176 (6): (3635-41). [PMID:16517732]
24. Zhong Y, Dong S, Strattan E, Ren L, Butchar JP, Thornton K, Mishra A, Porcu P, Bradshaw JM, Bisconte A et al.. (2015) Targeting interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK) using a novel covalent inhibitor PRN694.. J Biol Chem, 290 (10): (5960-78). [PMID:25593320]
25. Aronov AM, Tang Q, Martinez-Botella G, Bemis GW, Cao J, Chen G, Ewing NP, Ford PJ, Germann UA, Green J et al.. (2009) Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control.. J Med Chem, 52 (20): (6362-8). [PMID:19827834]
26. Kim KH, Maderna A, Schnute ME, Hegen M, Mohan S, Miyashiro J, Lin L, Li E, Keegan S, Lussier J et al.. (2011) Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis.. Bioorg Med Chem Lett, 21 (21): (6258-63). [PMID:21958547]
27. Hobson AD, Harris CM, van der Kam EL, Turner SC, Abibi A, Aguirre AL, Bousquet P, Kebede T, Konopacki DB, Gintant G et al.. (2015) Discovery of A-971432, An Orally Bioavailable Selective Sphingosine-1-Phosphate Receptor 5 (S1P5) Agonist for the Potential Treatment of Neurodegenerative Disorders.. J Med Chem, 58 (23): (9154-70). [PMID:26509640]
28. Wu H, Huang Q, Qi Z, Chen Y, Wang A, Chen C, Liang Q, Wang J, Chen W, Dong J et al.. (2017) Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model.. Sci Rep, 7 (1): (466). [PMID:28352114]
29. Telliez JB, Dowty ME, Wang L, Jussif J, Lin T, Li L, Moy E, Balbo P, Li W, Zhao Y et al.. (2016) Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition.. ACS Chem Biol, 11 (12): (3442-3451). [PMID:27791347]
30. Huang Z, Li H, Zhang Q, Lu F, Hong M, Zhang Z, Guo X, Zhu Y, Li S, Liu H. (2017) Discovery of Indolinone-Based Multikinase Inhibitors as Potential Therapeutics for Idiopathic Pulmonary Fibrosis.. ACS Med Chem Lett, 8 (11): (1142-1147). [PMID:29152045]
31. Bradshaw JM, McFarland JM, Paavilainen VO, Bisconte A, Tam D, Phan VT, Romanov S, Finkle D, Shu J, Patel V et al.. (2015) Prolonged and tunable residence time using reversible covalent kinase inhibitors.. Nat Chem Biol, 11 (7): (525-31). [PMID:26006010]
32. Burger MT, Nishiguchi G, Han W, Lan J, Simmons R, Atallah G, Ding Y, Tamez V, Zhang Y, Mathur M et al.. (2015) Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies.. J Med Chem, 58 (21): (8373-86). [PMID:26505898]
33. Watterson SH, De Lucca GV, Shi Q, Langevine CM, Liu Q, Batt DG, Beaudoin Bertrand M, Gong H, Dai J, Yip S et al.. (2016) Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton's Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers.. J Med Chem, 59 (19): (9173-9200). [PMID:27583770]
34. Patel S, Harris SF, Gibbons P, Deshmukh G, Gustafson A, Kellar T, Lin H, Liu X, Liu Y, Liu Y et al.. (2015) Scaffold-Hopping and Structure-Based Discovery of Potent, Selective, And Brain Penetrant N-(1H-Pyrazol-3-yl)pyridin-2-amine Inhibitors of Dual Leucine Zipper Kinase (DLK, MAP3K12).. J Med Chem, 58 (20): (8182-99). [PMID:26431428]
35. Das J, Furch JA, Liu C, Moquin RV, Lin J, Spergel SH, McIntyre KW, Shuster DJ, O'Day KD, Penhallow B et al.. (2006) Discovery and SAR of 2-amino-5-(thioaryl)thiazoles as potent and selective Itk inhibitors.. Bioorg Med Chem Lett, 16 (14): (3706-12). [PMID:16682193]
36. Liang C, Tian D, Ren X, Ding S, Jia M, Xin M, Thareja S. (2018) The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review.. Eur J Med Chem, 151 (3): (315-326). [PMID:29631132]
37. Kawahata W, Asami T, Kiyoi T, Irie T, Taniguchi H, Asamitsu Y, Inoue T, Miyake T, Sawa M. (2018) Design and Synthesis of Novel Amino-triazine Analogues as Selective Bruton's Tyrosine Kinase Inhibitors for Treatment of Rheumatoid Arthritis.. J Med Chem, 61 (19): (8917-8933). [PMID:30216722]
38. Li Y, Xiong Y, Zhang G, Zhang L, Yang W, Yang J, Huang L, Qiao Z, Miao Z, Lin G et al.. (2018) Identification of 5-(2,3-Dihydro-1 H-indol-5-yl)-7 H-pyrrolo[2,3- d]pyrimidin-4-amine Derivatives as a New Class of Receptor-Interacting Protein Kinase 1 (RIPK1) Inhibitors, Which Showed Potent Activity in a Tumor Metastasis Model.. J Med Chem, 61 (24): (11398-11414). [PMID:30480444]
39. Smith CR, Dougan DR, Komandla M, Kanouni T, Knight B, Lawson JD, Sabat M, Taylor ER, Vu P, Wyrick C. (2015) Fragment-Based Discovery of a Small Molecule Inhibitor of Bruton's Tyrosine Kinase.. J Med Chem, 58 (14): (5437-44). [PMID:26087137]
40. Yao X, Sun X, Jin S, Yang L, Xu H, Rao Y. (2019) Discovery of 4-Aminoquinoline-3-carboxamide Derivatives as Potent Reversible Bruton's Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis.. J Med Chem, 62 (14): (6561-6574). [PMID:31260299]
41. Caldwell RD, Qiu H, Askew BC, Bender AT, Brugger N, Camps M, Dhanabal M, Dutt V, Eichhorn T, Gardberg AS et al.. (2019) Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases.. J Med Chem, 62 (17): (7643-7655). [PMID:31368705]
42. Watterson SH, Liu Q, Beaudoin Bertrand M, Batt DG, Li L, Pattoli MA, Skala S, Cheng L, Obermeier MT, Moore R et al.. (2019) Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK).. J Med Chem, 62 (7): (3228-3250). [PMID:30893553]
43. Dobrovolsky D, Wang ES, Morrow S, Leahy C, Faust T, Nowak RP, Donovan KA, Yang G, Li Z, Fischer ES et al.. (2019) Bruton tyrosine kinase degradation as a therapeutic strategy for cancer.. Blood, 133 (9): (952-961). [PMID:30545835]
44. Angst D, Gessier F, Janser P, Vulpetti A, Wälchli R, Beerli C, Littlewood-Evans A, Dawson J, Nuesslein-Hildesheim B, Wieczorek G et al.. (2020) Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.. J Med Chem, 63 (10): (5102-5118). [PMID:32083858]
45. Ma B, Bohnert T, Otipoby KL, Tien E, Arefayene M, Bai J, Bajrami B, Bame E, Chan TR, Humora M et al.. (2020) Discovery of BIIB068: A Selective, Potent, Reversible Bruton's Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases.. J Med Chem, 63 (21): (12526-12541). [PMID:32696648]
46. Czako B, Marszalek JR, Burke JP, Mandal P, Leonard PG, Cross JB, Mseeh F, Jiang Y, Chang EQ, Suzuki E et al.. (2020) Discovery of IACS-9439, a Potent, Exquisitely Selective, and Orally Bioavailable Inhibitor of CSF1R.. J Med Chem, 129 (3): (589-97). [PMID:32787110]
47. Ghoshdastidar K, Patel H, Bhayani H, Patel A, Thakkar K, Patel D, Sharma M, Singh J, Mohapatra J, Chatterjee A et al.. (2020) ZYBT1, a potent, irreversible Bruton's Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer.. Pharmacol Res Perspect, 8 (4): (e00565). [PMID:32790160]
48. Reiff SD, Mantel R, Smith LL, Greene JT, Muhowski EM, Fabian CA, Goettl VM, Tran M, Harrington BK, Rogers KA et al.. (2018) The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation.. Cancer Discov, 8 (10): (1300-1315). [PMID:30093506]
49. Bond DA, Woyach JA. (2019) Targeting BTK in CLL: Beyond Ibrutinib.. Curr Hematol Malig Rep, 14 (3): (197-205). [PMID:31028669]
50. Yin L, Li H, Liu W, Yao Z, Cheng Z, Zhang H, Zou H. (2018) A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy.. Eur J Med Chem, 144 (3): (1-28). [PMID:29247857]
51. DiMauro EF, Newcomb J, Nunes JJ, Bemis JE, Boucher C, Buchanan JL, Buckner WH, Cee VJ, Chai L, Deak HL, Epstein LF, Faust T, Gallant P, Geuns-Meyer SD, Gore A, Gu Y, Henkle B, Hodous BL, Hsieh F, Huang X, Kim JL, Lee JH, Martin MW, Masse CE, McGowan DC, Metz D, Mohn D, Morgenstern KA, Oliveira-dos-Santos A, Patel VF, Powers D, Rose PE, Schneider S, Tomlinson SA, Tudor YY, Turci SM, Welcher AA, White RD, Zhao H, Zhu L, Zhu X.. (2006) Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity.. J Med Chem, 49 (19): (5671-5686). [PMID:16970394]
52. Green N, Hu Y, Janz K, Li HQ, Kaila N, Guler S, Thomason J, Joseph-McCarthy D, Tam SY, Hotchandani R, Wu J, Huang A, Wang Q, Leung L, Pelker J, Marusic S, Hsu S, Telliez JB, Hall JP, Cuozzo JW, Lin LL.. (2007) Inhibitors of tumor progression loci-2 (Tpl2) kinase and tumor necrosis factor alpha (TNF-alpha) production: selectivity and in vivo antiinflammatory activity of novel 8-substituted-4-anilino-6-aminoquinoline-3-carbonitriles.. J Med Chem, 50 (19): (4728-4745). [PMID:17715908]
53. Martin MW, Newcomb J, Nunes JJ, Boucher C, Chai L, Epstein LF, Faust T, Flores S, Gallant P, Gore A, Gu Y, Hsieh F, Huang X, Kim JL, Middleton S, Morgenstern K, Oliveira-dos-Santos A, Patel VF, Powers D, Rose P, Tudor Y, Turci SM, Welcher AA, Zack D, Zhao H, Zhu L, Zhu X, Ghiron C, Ermann M, Johnston D, Saluste CG.. (2008) Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.. J Med Chem, 51 (6): (1637-1648). [PMID:18278858]
54. Hantschel O, Rix U, Schmidt U, Bürckstümmer T, Kneidinger M, Schütze G, Colinge J, Bennett KL, Ellmeier W, Valent P, Superti-Furga G.. (2007) The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib.. Proc Natl Acad Sci U S A, 104 (33): (13283-13288). [PMID:17684099]
55. McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J, Archibald H, Raudales R, Tam A, Lee D, Rothenberg SM, Supko JG, Sordella R, Ulkus LE, Iafrate AJ, Maheswaran S, Njauw CN, Tsao H, Drew L, Hanke JH, Ma XJ, Erlander MG, Gray NS, Haber DA, Settleman J.. (2007) Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.. Proc Natl Acad Sci U S A, 104 (50): (19936-19941). [PMID:18077425]
56. Slack-Davis JK, Martin KH, Tilghman RW, Iwanicki M, Ung EJ, Autry C, Luzzio MJ, Cooper B, Kath JC, Roberts WG, Parsons JT.. (2007) Cellular characterization of a novel focal adhesion kinase inhibitor.. J Biol Chem, 282 (20): (14845-14852). [PMID:17395594]
57. Feng Y, Yin Y, Weiser A, Griffin E, Cameron MD, Lin L, Ruiz C, Schürer SC, Inoue T, Rao PV, Schröter T, Lograsso P.. (2008) Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors.. J Med Chem, 51 (21): (6642-6645). [PMID:18834107]
58. Xia Z, Knaak C, Ma J, Beharry ZM, McInnes C, Wang W, Kraft AS, Smith CD.. (2009) Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases.. J Med Chem, 52 (1): (74-86). [PMID:19072652]
59. D'Angelo ND, Bellon SF, Booker SK, Cheng Y, Coxon A, Dominguez C, Fellows I, Hoffman D, Hungate R, Kaplan-Lefko P, Lee MR, Li C, Liu L, Rainbeau E, Reider PJ, Rex K, Siegmund A, Sun Y, Tasker AS, Xi N, Xu S, Yang Y, Zhang Y, Burgess TL, Dussault I, Kim TS.. (2008) Design, synthesis, and biological evaluation of potent c-Met inhibitors.. J Med Chem, 51 (18): (5766-5779). [PMID:18763753]
60. Cole DC, Asselin M, Brennan A, Czerwinski R, Ellingboe JW, Fitz L, Greco R, Huang X, Joseph-McCarthy D, Kelly MF, Kirisits M, Lee J, Li Y, Morgan P, Stock JR, Tsao DH, Wissner A, Yang X, Chaudhary D.. (2008) Identification, characterization and initial hit-to-lead optimization of a series of 4-arylamino-3-pyridinecarbonitrile as protein kinase C theta (PKCtheta) inhibitors.. J Med Chem, 51 (19): (5958-5963). [PMID:18783200]
61. Hur W, Velentza A, Kim S, Flatauer L, Jiang X, Valente D, Mason DE, Suzuki M, Larson B, Zhang J, Zagorska A, Didonato M, Nagle A, Warmuth M, Balk SP, Peters EC, Gray NS.. (2008) Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase.. Bioorg Med Chem Lett, 18 (22): (5916-5919). [PMID:18667312]
62. Gopalsamy A, Ciszewski G, Hu Y, Lee F, Feldberg L, Frommer E, Kim S, Collins K, Wojciechowicz D, Mallon R.. (2009) Identification of pyrazolo[1,5-a]pyrimidine-3-carboxylates as B-Raf kinase inhibitors.. Bioorg Med Chem Lett, 19 (10): (2735-2738). [PMID:19362830]
63. Li J, Kaoud TS, Laroche C, Dalby KN, Kerwin SM.. (2009) Synthesis and biological evaluation of p38alpha kinase-targeting dialkynylimidazoles.. Bioorg Med Chem Lett, 19 (22): (6293-6297). [PMID:19822424]
64. Shomin CD, Meyer SC, Ghosh I.. (2009) Staurosporine tethered peptide ligands that target cAMP-dependent protein kinase (PKA): optimization and selectivity profiling.. Bioorg Med Chem, 17 (17): (6196-6202). [PMID:19674907]
65. Wee XK, Yeo WK, Zhang B, Tan VB, Lim KM, Tay TE, Go ML.. (2009) Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.. Bioorg Med Chem, 17 (21): (7562-7571). [PMID:19783149]
66. Qiao L, Choi S, Case A, Gainer TG, Seyb K, Glicksman MA, Lo DC, Stein RL, Cuny GD.. (2009) Structure-activity relationship study of EphB3 receptor tyrosine kinase inhibitors.. Bioorg Med Chem Lett, 19 (21): (6122-6126). [PMID:19783434]
67. Yu H, Jung Y, Kim H, Lee J, Oh CH, Yoo KH, Sim T, Hah JM.. (2010) 1,4-dihydropyrazolo[4,3-d]imidazole phenyl derivatives: a novel type II Raf kinase inhibitors.. Bioorg Med Chem Lett, 20 (12): (3805-3808). [PMID:20466542]
68. Deng X, Lim SM, Zhang J, Gray NS.. (2010) Broad spectrum alkynyl inhibitors of T315I Bcr-Abl.. Bioorg Med Chem Lett, 20 (14): (4196-4200). [PMID:20541934]
69. Ye P, Kuhn C, Juan M, Sharma R, Connolly B, Alton G, Liu H, Stanton R, Kablaoui NM.. (2011) Potent and selective thiophene urea-templated inhibitors of S6K.. Bioorg Med Chem Lett, 21 (2): (849-852). [PMID:21185721]
70. Probst GD, Bowers S, Sealy JM, Truong AP, Hom RK, Galemmo RA, Konradi AW, Sham HL, Quincy DA, Pan H, Yao N, Lin M, Tóth G, Artis DR, Zmolek W, Wong K, Qin A, Lorentzen C, Nakamura DF, Quinn KP, Sauer JM, Powell K, Ruslim L, Wright S, Chereau D, Ren Z, Anderson JP, Bard F, Yednock TA, Griswold-Prenner I.. (2011) Highly selective c-Jun N-terminal kinase (JNK) 2 and 3 inhibitors with in vitro CNS-like pharmacokinetic properties prevent neurodegeneration.. Bioorg Med Chem Lett, 21 (1): (315-319). [PMID:21112785]
71. Charrier JD, Miller A, Kay DP, Brenchley G, Twin HC, Collier PN, Ramaya S, Keily SB, Durrant SJ, Knegtel RM, Tanner AJ, Brown K, Curnock AP, Jimenez JM.. (2011) Discovery and structure-activity relationship of 3-aminopyrid-2-ones as potent and selective interleukin-2 inducible T-cell kinase (Itk) inhibitors.. J Med Chem, 54 (7): (2341-2350). [PMID:21391610]
72. Lumeras W, Vidal L, Vidal B, Balagué C, Orellana A, Maldonado M, Domínguez M, Segarra V, Caturla F.. (2011) 1,7-Naphthyridine 1-oxides as novel potent and selective inhibitors of p38 mitogen activated protein kinase.. J Med Chem, 54 (22): (7899-7910). [PMID:21999461]
73. Powell NA, Kohrt JT, Filipski KJ, Kaufman M, Sheehan D, Edmunds JE, Delaney A, Wang Y, Bourbonais F, Lee DY, Schwende F, Sun F, McConnell P, Catana C, Chen H, Ohren J, Perrin LA.. (2012) Novel and selective spiroindoline-based inhibitors of Sky kinase.. Bioorg Med Chem Lett, 22 (1): (190-193). [PMID:22119469]
74. Cuny GD, Ulyanova NP, Patnaik D, Liu JF, Lin X, Auerbach K, Ray SS, Xian J, Glicksman MA, Stein RL, Higgins JM.. (2012) Structure-activity relationship study of beta-carboline derivatives as haspin kinase inhibitors.. Bioorg Med Chem Lett, 22 (5): (2015-2019). [PMID:22335895]
75. Zhang J, Deng X, Choi HG, Alessi DR, Gray NS.. (2012) Characterization of TAE684 as a potent LRRK2 kinase inhibitor.. Bioorg Med Chem Lett, 22 (5): (1864-1869). [PMID:22335897]
76. Illig CR, Manthey CL, Wall MJ, Meegalla SK, Chen J, Wilson KJ, Ballentine SK, Desjarlais RL, Schubert C, Crysler CS, Chen Y, Molloy CJ, Chaikin MA, Donatelli RR, Yurkow E, Zhou Z, Player MR, Tomczuk BE.. (2011) Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).. J Med Chem, 54 (22): (7860-7883). [PMID:22039836]
77. Sunose M, Bell K, Ellard K, Bergamini G, Neubauer G, Werner T, Ramsden N.. (2012) Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease.. Bioorg Med Chem Lett, 22 (14): (4613-4618). [PMID:22726925]
78. Reith AD, Bamborough P, Jandu K, Andreotti D, Mensah L, Dossang P, Choi HG, Deng X, Zhang J, Alessi DR, Gray NS.. (2012) GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor.. Bioorg Med Chem Lett, 22 (17): (5625-5629). [PMID:22863203]
79. Lafleur K, Dong J, Huang D, Caflisch A, Nevado C.. (2013) Optimization of inhibitors of the tyrosine kinase EphB4. 2. Cellular potency improvement and binding mode validation by X-ray crystallography.. J Med Chem, 56 (1): (84-96). [PMID:23253074]
80. Dolečková I, Cesnek M, Dračinský M, Brynda J, Voller J, Janeba Z, Kryštof V.. (2013) Synthesis and biological evaluation of guanidino analogues of roscovitine.. Eur J Med Chem, 62 (443-452). [PMID:23399722]
81. Brown A, Shi Q, Moore TW, Yoon Y, Prussia A, Maddox C, Liotta DC, Shim H, Snyder JP.. (2013) Monocarbonyl curcumin analogues: heterocyclic pleiotropic kinase inhibitors that mediate anticancer properties.. J Med Chem, 56 (9): (3456-3466). [PMID:23550937]
82. Mortensen DS, Sapienza J, Lee BG, Perrin-Ninkovic SM, Harris R, Shevlin G, Parnes JS, Whitefield B, Hickman M, Khambatta G, Bisonette RR, Peng S, Gamez JC, Leisten J, Narla RK, Fultz KE, Sankar S.. (2013) Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase.. Bioorg Med Chem Lett, 23 (6): (1588-1591). [PMID:23414803]
83. Lin WH, Hsu JT, Hsieh SY, Chen CT, Song JS, Yen SC, Hsu T, Lu CT, Chen CH, Chou LH, Yang YN, Chiu CH, Chen CP, Tseng YJ, Yen KJ, Yeh CF, Chao YS, Yeh TK, Jiaang WT.. (2013) Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).. Bioorg Med Chem, 21 (11): (2856-2867). [PMID:23618709]
84. Bowers S, Truong AP, Ye M, Aubele DL, Sealy JM, Neitz RJ, Hom RK, Chan W, Dappen MS, Galemmo RA, Konradi AW, Sham HL, Zhu YL, Beroza P, Tonn G, Zhang H, Hoffman J, Motter R, Fauss D, Tanaka P, Bova MP, Ren Z, Tam D, Ruslim L, Baker J, Pandya D, Diep L, Fitzgerald K, Artis DR, Anderson JP, Bergeron M.. (2013) Design and synthesis of highly selective, orally active Polo-like kinase-2 (Plk-2) inhibitors.. Bioorg Med Chem Lett, 23 (9): (2743-2749). [PMID:23522834]
85. Zhou W, Liu X, Tu Z, Zhang L, Ku X, Bai F, Zhao Z, Xu Y, Ding K, Ding K, Li H.. (2013) Discovery of pteridin-7(8H)-one-based irreversible inhibitors targeting the epidermal growth factor receptor (EGFR) kinase T790M/L858R mutant.. J Med Chem, 56 (20): (7821-7837). [PMID:24053674]
86. Alder CM, Ambler M, Campbell AJ, Champigny AC, Deakin AM, Harling JD, Harris CA, Longstaff T, Lynn S, Maxwell AC, Mooney CJ, Scullion C, Singh OM, Smith IE, Somers DO, Tame CJ, Wayne G, Wilson C, Woolven JM.. (2013) Identification of a Novel and Selective Series of Itk Inhibitors via a Template-Hopping Strategy.. ACS Med Chem Lett, 4 (10): (948-952). [PMID:24900590]
87. Cheng X, Merz KH, Vatter S, Christ J, Wölfl S, Eisenbrand G.. (2014) 7,7'-Diazaindirubin--a small molecule inhibitor of casein kinase 2 in vitro and in cells.. Bioorg Med Chem, 22 (1): (247-255). [PMID:24326279]
88. Shi Q, Tebben A, Dyckman AJ, Li H, Liu C, Lin J, Spergel S, Burke JR, McIntyre KW, Olini GC, Strnad J, Surti N, Muckelbauer JK, Chang C, An Y, Cheng L, Ruan Q, Leftheris K, Carter PH, Tino J, De Lucca GV.. (2014) Purine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseases.. Bioorg Med Chem Lett, 24 (9): (2206-2211). [PMID:24685542]
89. Rechfeld F, Gruber P, Kirchmair J, Boehler M, Hauser N, Hechenberger G, Garczarczyk D, Lapa GB, Preobrazhenskaya MN, Goekjian P, Langer T, Hofmann J.. (2014) Thienoquinolines as novel disruptors of the PKCε/RACK2 protein-protein interaction.. J Med Chem, 57 (8): (3235-3246). [PMID:24712764]
90. Park CH, Lee C, Yang JS, Joe BY, Chun K, Kim H, Kim HY, Kang JS, Lee JI, Kim MH, Han G.. (2014) Discovery of thienopyrimidine-based FLT3 inhibitors from the structural modification of known IKKβ inhibitors.. Bioorg Med Chem Lett, 24 (12): (2655-2660). [PMID:24813730]
91. Blake JF, Gaudino JJ, De Meese J, Mohr P, Chicarelli M, Tian H, Garrey R, Thomas A, Siedem CS, Welch MB, Kolakowski G, Kaus R, Burkard M, Martinson M, Chen H, Dean B, Dudley DA, Gould SE, Pacheco P, Shahidi-Latham S, Wang W, West K, Yin J, Moffat J, Schwarz JB.. (2014) Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2.. Bioorg Med Chem Lett, 24 (12): (2635-2639). [PMID:24813737]
92. Puig de la Bellacasa R, Roué G, Balsas P, Pérez-Galán P, Teixidó J, Colomer D, Borrell JI.. (2014) 4-Amino-2-arylamino-6-(2,6-dichlorophenyl)-pyrido[2,3-d]pyrimidin-7-(8H)-ones as BCR kinase inhibitors for B lymphoid malignancies.. Eur J Med Chem, 86 (664-675). [PMID:25222877]
93. Zhao X, Xin M, Huang W, Ren Y, Jin Q, Tang F, Jiang H, Wang Y, Yang J, Mo S, Xiang H.. (2015) Design, synthesis and evaluation of novel 5-phenylpyridin-2(1H)-one derivatives as potent reversible Bruton's tyrosine kinase inhibitors.. Bioorg Med Chem, 23 (2): (348-364). [PMID:25515957]
94. Muth F, Günther M, Bauer SM, Döring E, Fischer S, Maier J, Drückes P, Köppler J, Trappe J, Rothbauer U, Koch P, Laufer SA.. (2015) Tetra-substituted pyridinylimidazoles as dual inhibitors of p38α mitogen-activated protein kinase and c-Jun N-terminal kinase 3 for potential treatment of neurodegenerative diseases.. J Med Chem, 58 (1): (443-456). [PMID:25475894]
95. Lawrence HR, Mahajan K, Luo Y, Zhang D, Tindall N, Huseyin M, Gevariya H, Kazi S, Ozcan S, Mahajan NP, Lawrence NJ.. (2015) Development of novel ACK1/TNK2 inhibitors using a fragment-based approach.. J Med Chem, 58 (6): (2746-2763). [PMID:25699576]
96. Zhang CH, Zheng MW, Li YP, Lin XD, Huang M, Zhong L, Li GB, Zhang RJ, Lin WT, Jiao Y, Wu XA, Yang J, Xiang R, Chen LJ, Zhao YL, Cheng W, Wei YQ, Yang SY.. (2015) Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer.. J Med Chem, 58 (9): (3957-3974). [PMID:25835317]
97. Chen CT, Hsu JT, Lin WH, Lu CT, Yen SC, Hsu T, Huang YL, Song JS, Chen CH, Chou LH, Yen KJ, Chen CP, Kuo PC, Huang CL, Liu HE, Chao YS, Yeh TK, Jiaang WT.. (2015) Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations.. Eur J Med Chem, 100 (151-161). [PMID:26081023]
98. Tan L, Akahane K, McNally R, Reyskens KM, Ficarro SB, Liu S, Herter-Sprie GS, Koyama S, Pattison MJ, Labella K, Johannessen L, Akbay EA, Wong KK, Frank DA, Marto JA, Look TA, Arthur JS, Eck MJ, Gray NS.. (2015) Development of Selective Covalent Janus Kinase 3 Inhibitors.. J Med Chem, 58 (16): (6589-6606). [PMID:26258521]
99. Lin XD, Yang HW, Ma S, Li WW, Zhang CH, Wang WJ, Xiang R, Li LL, Yang SY.. (2015) Discovery of 6-phenylimidazo[2,1-b]thiazole derivatives as a new type of FLT3 inhibitors.. Bioorg Med Chem Lett, 25 (20): (4534-4538). [PMID:26342867]
100. Charnley AK, Convery MA, Lakdawala Shah A, Jones E, Hardwicke P, Bridges A, Ouellette M, Totoritis R, Schwartz B, King BW, Wisnoski DD, Kang J, Eidam PM, Votta BJ, Gough PJ, Marquis RW, Bertin J, Casillas L.. (2015) Crystal structures of human RIP2 kinase catalytic domain complexed with ATP-competitive inhibitors: Foundations for understanding inhibitor selectivity.. Bioorg Med Chem, 23 (21): (7000-7006). [PMID:26455654]
101. Sestito S, Nesi G, Daniele S, Martelli A, Digiacomo M, Borghini A, Pietra D, Calderone V, Lapucci A, Falasca M, Parrella P, Notarangelo A, Breschi MC, Macchia M, Martini C, Rapposelli S.. (2015) Design and synthesis of 2-oxindole based multi-targeted inhibitors of PDK1/Akt signaling pathway for the treatment of glioblastoma multiforme.. Eur J Med Chem, 105 (274-288). [PMID:26498573]
102. Li X, Wang A, Yu K, Qi Z, Chen C, Wang W, Hu C, Wu H, Wu J, Zhao Z, Liu J, Zou F, Wang L, Wang B, Wang W, Zhang S, Liu J, Liu Q.. (2015) Discovery of (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia.. J Med Chem, 58 (24): (9625-9638). [PMID:26630553]
103. Bavetsias V, Lanigan RM, Ruda GF, Atrash B, McLaughlin MG, Tumber A, Mok NY, Le Bihan YV, Dempster S, Boxall KJ, Jeganathan F, Hatch SB, Savitsky P, Velupillai S, Krojer T, England KS, Sejberg J, Thai C, Donovan A, Pal A, Scozzafava G, Bennett JM, Kawamura A, Johansson C, Szykowska A, Gileadi C, Burgess-Brown NA, von Delft F, Oppermann U, Walters Z, Shipley J, Raynaud FI, Westaway SM, Prinjha RK, Fedorov O, Burke R, Schofield CJ, Westwood IM, Bountra C, Müller S, van Montfort RL, Brennan PE, Blagg J.. (2016) 8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors.. J Med Chem, 59 (4): (1388-1409). [PMID:26741168]
104. Schiemann K, Mallinger A, Wienke D, Esdar C, Poeschke O, Busch M, Rohdich F, Eccles SA, Schneider R, Raynaud FI, Czodrowski P, Musil D, Schwarz D, Urbahns K, Blagg J.. (2016) Discovery of potent and selective CDK8 inhibitors from an HSP90 pharmacophore.. Bioorg Med Chem Lett, 26 (5): (1443-1451). [PMID:26852363]
105. Huang Z, Zhang Q, Yan L, Zhong G, Zhang L, Tan X, Wang Y.. (2016) Approaching the active conformation of 1,3-diaminopyrimidine based covalent inhibitors of Bruton's tyrosine kinase for treatment of Rheumatoid arthritis.. Bioorg Med Chem Lett, 26 (8): (1954-1957). [PMID:26976214]
106. Daydé-Cazals B, Fauvel B, Singer M, Feneyrolles C, Bestgen B, Gassiot F, Spenlinhauer A, Warnault P, Van Hijfte N, Borjini N, Chevé G, Yasri A.. (2016) Rational Design, Synthesis, and Biological Evaluation of 7-Azaindole Derivatives as Potent Focused Multi-Targeted Kinase Inhibitors.. J Med Chem, 59 (8): (3886-3905). [PMID:27010810]
107. Schroeder RL, Goyal N, Bratton M, Townley I, Pham NA, Tram P, Stone T, Geathers J, Nguyen K, Sridhar J.. (2016) Identification of quinones as novel PIM1 kinase inhibitors.. Bioorg Med Chem Lett, 26 (13): (3187-3191). [PMID:27173800]
108. Kumar V, Guru SK, Jain SK, Joshi P, Gandhi SG, Bharate SB, Bhushan S, Bharate SS, Vishwakarma RA.. (2016) A chromatography-free isolation of rohitukine from leaves of Dysoxylum binectariferum: Evaluation for in vitro cytotoxicity, Cdk inhibition and physicochemical properties.. Bioorg Med Chem Lett, 26 (15): (3457-3463). [PMID:27363938]
109. Kim H, Lee C, Yang JS, Choi S, Park CH, Kang JS, Oh SJ, Yun J, Kim MH, Han G.. (2016) Structural modifications at the 6-position of thieno[2,3-d]pyrimidines and their effects on potency at FLT3 for treatment of acute myeloid leukemia.. Eur J Med Chem, 120 (74-85). [PMID:27187860]
110. Ge Y, Jin Y, Wang C, Zhang J, Tang Z, Peng J, Liu K, Li Y, Zhou Y, Ma X.. (2016) Discovery of Novel Bruton's Tyrosine Kinase (BTK) Inhibitors Bearing a N,9-Diphenyl-9H-purin-2-amine Scaffold.. ACS Med Chem Lett, 7 (12): (1050-1055). [PMID:27994736]
111. Pujala B, Agarwal AK, Middya S, Banerjee M, Surya A, Nayak AK, Gupta A, Khare S, Guguloth R, Randive NA, Shinde BU, Thakur A, Patel DI, Raja M, Green MJ, Alfaro J, Avila P, Pérez de Arce F, Almirez RG, Kanno S, Bernales S, Hung DT, Chakravarty S, McCullagh E, Quinn KP, Rai R, Pham SM.. (2016) Discovery of Pyrazolopyrimidine Derivatives as Novel Dual Inhibitors of BTK and PI3Kδ.. ACS Med Chem Lett, 7 (12): (1161-1166). [PMID:27994757]
112. Ge Y, Yang H, Wang C, Meng Q, Li L, Sun H, Zhen Y, Liu K, Li Y, Ma X.. (2017) Design and synthesis of phosphoryl-substituted diphenylpyrimidines (Pho-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors: Targeted treatment of B lymphoblastic leukemia cell lines.. Bioorg Med Chem, 25 (2): (765-772). [PMID:27956037]
113. Klaeger S, Heinzlmeir S and Wilhelm M et al. (2017) The target landscape of clinical kinase drugs.. Science, 358 (6367): [PMID:29191878]
114. Chen Y, Zheng Y, Jiang Q, Qin F, Zhang Y, Fu L, He G.. (2017) Integrated bioinformatics, computational and experimental methods to discover novel Raf/extracellular-signal regulated kinase (ERK) dual inhibitors against breast cancer cells.. Eur J Med Chem, 127 (997-1011). [PMID:27839788]
115. Argyros O, Lougiakis N, Kouvari E, Papafotika A, Raptopoulou CP, Psycharis V, Christoforidis S, Pouli N, Marakos P, Tamvakopoulos C.. (2017) Design and synthesis of novel 7-aminosubstituted pyrido[2,3-b]pyrazines exhibiting anti-breast cancer activity.. Eur J Med Chem, 126 (954-968). [PMID:28006668]
116. Hoemann M, Wilson N, Argiriadi M, Banach D, Burchat A, Calderwood D, Clapham B, Cox P, Duignan DB, Konopacki D, Somal G, Vasudevan A.. (2016) Synthesis and optimization of furano[3,2-d]pyrimidines as selective spleen tyrosine kinase (Syk) inhibitors.. Bioorg Med Chem Lett, 26 (22): (5562-5567). [PMID:27789138]
117. Wang S, Xu L, Lu YT, Liu YF, Han B, Liu T, Tang J, Li J, Wu J, Li JY, Yu LF, Yang F.. (2017) Discovery of benzofuran-3(2H)-one derivatives as novel DRAK2 inhibitors that protect islet β-cells from apoptosis.. Eur J Med Chem, 130 (195-208). [PMID:28249207]
118. Wang Y, Sun Y, Cao R, Liu D, Xie Y, Li L, Qi X, Huang N.. (2017) In Silico Identification of a Novel Hinge-Binding Scaffold for Kinase Inhibitor Discovery.. J Med Chem, 60 (20): (8552-8564). [PMID:28945083]
119. Crawford JJ, Johnson AR, Misner DL, Belmont LD, Castanedo G, Choy R, Coraggio M, Dong L, Eigenbrot C, Erickson R, Ghilardi N, Hau J, Katewa A, Kohli PB, Lee W, Lubach JW, McKenzie BS, Ortwine DF, Schutt L, Tay S, Wei B, Reif K, Liu L, Wong H, Young WB.. (2018) Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.. J Med Chem, 61 (6): (2227-2245). [PMID:29457982]
120. Zhou D, Springer MZ, Xu D, Liu D, Hudmon A, Macleod KF, Meroueh SO.. (2017) Small molecules inhibit STAT3 activation, autophagy, and cancer cell anchorage-independent growth.. Bioorg Med Chem, 25 (12): (2995-3005). [PMID:28438385]
121. Wang X, Barbosa J, Blomgren P, Bremer MC, Chen J, Crawford JJ, Deng W, Dong L, Eigenbrot C, Gallion S, Hau J, Hu H, Johnson AR, Katewa A, Kropf JE, Lee SH, Liu L, Lubach JW, Macaluso J, Maciejewski P, Mitchell SA, Ortwine DF, DiPaolo J, Reif K, Scheerens H, Schmitt A, Wong H, Xiong JM, Xu J, Zhao Z, Zhou F, Currie KS, Young WB.. (2017) Discovery of Potent and Selective Tricyclic Inhibitors of Bruton's Tyrosine Kinase with Improved Druglike Properties.. ACS Med Chem Lett, 8 (6): (608-613). [PMID:28626519]
122. Yamada K, Levell J, Yoon T, Kohls D, Yowe D, Rigel DF, Imase H, Yuan J, Yasoshima K, DiPetrillo K, Monovich L, Xu L, Zhu M, Kato M, Jain M, Idamakanti N, Taslimi P, Kawanami T, Argikar UA, Kunjathoor V, Xie X, Yagi YI, Iwaki Y, Robinson Z, Park HM.. (2017) Optimization of Allosteric With-No-Lysine (WNK) Kinase Inhibitors and Efficacy in Rodent Hypertension Models.. J Med Chem, 60 (16): (7099-7107). [PMID:28771350]
123. Smith GP, Badolo L, Chell V, Chen IJ, Christensen KV, David L, Daechsel JA, Hentzer M, Herzig MC, Mikkelsen GK, Watson SP, Williamson DS.. (2017) The design and SAR of a novel series of 2-aminopyridine based LRRK2 inhibitors.. Bioorg Med Chem Lett, 27 (18): (4500-4505). [PMID:28802631]
124. Sugimoto Y, Sawant DB, Fisk HA, Mao L, Li C, Chettiar S, Li PK, Darby MV, Brueggemeier RW.. (2017) Novel pyrrolopyrimidines as Mps1/TTK kinase inhibitors for breast cancer.. Bioorg Med Chem, 25 (7): (2156-2166). [PMID:28259529]
125. Wang A, Li X, Wu H, Zou F, Yan XE, Chen C, Hu C, Yu K, Wang W, Zhao P, Wu J, Qi Z, Wang W, Wang B, Wang L, Ren T, Zhang S, Yun CH, Liu J, Liu Q.. (2017) Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode.. J Med Chem, 60 (7): (2944-2962). [PMID:28282122]
126. Juchum M, Günther M, Döring E, Sievers-Engler A, Lämmerhofer M, Laufer S.. (2017) Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping.. J Med Chem, 60 (11): (4636-4656). [PMID:28482151]
127. Zhang H, Wu W, Feng C, Liu Z, Bai E, Wang X, Lei M, Cheng H, Feng H, Shi J, Wang J, Zhang Z, Jin T, Chen S, Hu S, Zhu Y.. (2017) Design, synthesis, SAR discussion, in vitro and in vivo evaluation of novel selective EGFR modulator to inhibit L858R/T790M double mutants.. Eur J Med Chem, 135 (12-23). [PMID:28426996]
128. Liu H, Qu M, Xu L, Han X, Wang C, Shu X, Yao J, Liu K, Peng J, Li Y, Ma X.. (2017) Design and synthesis of sulfonamide-substituted diphenylpyrimidines (SFA-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B-cell lymphoblastic leukemia.. Eur J Med Chem, 135 (60-69). [PMID:28432946]
129. Fukuda T, Goto R, Kiho T, Ueda K, Muramatsu S, Hashimoto M, Aki A, Watanabe K, Tanaka N.. (2017) Discovery of DS79182026: A potent orally active hepcidin production inhibitor.. Bioorg Med Chem Lett, 27 (16): (3716-3722). [PMID:28705644]
130. Boga SB, Alhassan AB, Liu J, Guiadeen D, Krikorian A, Gao X, Wang J, Yu Y, Anand R, Liu S, Yang C, Wu H, Cai J, Zhu H, Desai J, Maloney K, Gao YD, Fischmann TO, Presland J, Mansueto M, Xu Z, Leccese E, Knemeyer I, Garlisi CG, Bays N, Stivers P, Brandish PE, Hicks A, Cooper A, Kim RM, Kozlowski JA.. (2017) Discovery of 3-morpholino-imidazole[1,5-a]pyrazine BTK inhibitors for rheumatoid arthritis.. Bioorg Med Chem Lett, 27 (16): (3939-3943). [PMID:28720503]
131. He L, Li D, Zhang C, Bai P, Chen L.. (2017) Discovery of (R)-5-(benzo[d][1,3]dioxol-5-yl)-7-((1-(vinylsulfonyl)pyrrolidin-2-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (B6) as a potent Bmx inhibitor for the treatment of NSCLC.. Bioorg Med Chem Lett, 27 (17): (4171-4175). [PMID:28734581]
132. Patel S, Meilandt WJ, Erickson RI, Chen J, Deshmukh G, Estrada AA, Fuji RN, Gibbons P, Gustafson A, Harris SF, Imperio J, Liu W, Liu X, Liu Y, Lyssikatos JP, Ma C, Yin J, Lewcock JW, Siu M.. (2017) Selective Inhibitors of Dual Leucine Zipper Kinase (DLK, MAP3K12) with Activity in a Model of Alzheimer's Disease.. J Med Chem, 60 (19): (8083-8102). [PMID:28929759]
133. Fukuda T, Goto R, Kiho T, Ueda K, Muramatsu S, Hashimoto M, Aki A, Watanabe K, Tanaka N.. (2017) Discovery of DS28120313 as a potent orally active hepcidin production inhibitor: Design and optimization of novel 4,6-disubstituted indazole derivatives.. Bioorg Med Chem Lett, 27 (23): (5252-5257). [PMID:29079471]
134. Farag AK, Elkamhawy A, Londhe AM, Lee KT, Pae AN, Roh EJ.. (2017) Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.. Eur J Med Chem, 141 (657-675). [PMID:29107425]
135. Reiersølmoen AC, Han J, Sundby E, Hoff BH.. (2018) Identification of fused pyrimidines as interleukin 17 secretion inhibitors.. Eur J Med Chem, 155 (562-578). [PMID:29909341]
136. Thakkar M, Bhuniya D, Kaduskar R, Mengawade T, Naik K, Salunkhe V, Bhalerao A, Kurhade S, Mavinahalli J, Jain V, Petla R, Avaragolla S, Ray S, Rouduri S, Dhanave A, De S, Pathade V, Tambe A, Raje AA, Madgula V, Joshi S, Nadeem A, Bala M, Umrani D, Hariharan N, Kulkarni B, Mookhtiar KA.. (2017) Discovery and evaluation of 1H-pyrrolo[2,3-b]pyridine based selective and reversible small molecule BTK inhibitors for the treatment of rheumatoid arthritis.. Bioorg Med Chem Lett, 27 (8): (1867-1873). [PMID:28279528]
137. Malínková V, Řezníčková E, Jorda R, Gucký T, Kryštof V.. (2017) Trisubstituted purine inhibitors of PDGFRα and their antileukemic activity in the human eosinophilic cell line EOL-1.. Bioorg Med Chem, 25 (24): (6523-6535). [PMID:29089259]
138. Liu H, Wu B, Ge Y, Huang J, Song S, Wang C, Yao J, Liu K, Li Y, Li Y, Ma X.. (2017) Phosphamide-containing diphenylpyrimidine analogues (PA-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with enhanced activity against pancreatic cancer cell lines.. Bioorg Med Chem, 25 (24): (6313-6321). [PMID:29102081]
139. Kawahata W, Asami T, Irie T, Sawa M.. (2018) Design and synthesis of novel pyrimidine analogs as highly selective, non-covalent BTK inhibitors.. Bioorg Med Chem Lett, 28 (2): (145-151). [PMID:29198867]
140. Monastyrskyi A, Nilchan N, Quereda V, Noguchi Y, Ruiz C, Grant W, Cameron M, Duckett D, Roush W.. (2018) Development of dual casein kinase 1δ/1ε (CK1δ/ε) inhibitors for treatment of breast cancer.. Bioorg Med Chem, 26 (3): (590-602). [PMID:29289448]
141. Zheng N, Pan J, Hao Q, Li Y, Zhou W.. (2018) Design, synthesis and biological evaluation of novel 3-substituted pyrazolopyrimidine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors.. Bioorg Med Chem, 26 (8): (2165-2172). [PMID:29567295]
142. Assadieskandar A, Yu C, Maisonneuve P, Liu X, Chen YC, Prakash GKS, Kurinov I, Sicheri F, Zhang C.. (2018) Effects of rigidity on the selectivity of protein kinase inhibitors.. Eur J Med Chem, 146 (519-528). [PMID:29407977]
143. Wang Q, Liu F, Qi S, Qi Z, Yan XE, Wang B, Wang A, Wang W, Chen C, Liu X, Jiang Z, Hu Z, Wang L, Wang W, Ren T, Zhang S, Yun CH, Liu Q, Liu J.. (2018) Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia.. Eur J Med Chem, 150 (366-384). [PMID:29544149]
144. He LJ, Yang DL, Li SQ, Zhang YJ, Tang Y, Lei J, Frett B, Lin HK, Li HY, Chen ZZ, Xu ZG.. (2018) Facile construction of fused benzimidazole-isoquinolinones that induce cell-cycle arrest and apoptosis in colorectal cancer cells.. Bioorg Med Chem, 26 (14): (3899-3908). [PMID:29921474]
145. Wang C, Li S, Meng Q, Sun X, Li H, Shu X, Sun H, Liu K, Liu Z, Ma X.. (2018) Novel amino acid-substituted diphenylpyrimidine derivatives as potent BTK inhibitors against B cell lymphoma cell lines.. Bioorg Med Chem, 26 (14): (4179-4186). [PMID:30006143]
146. Liu L, Shi B, Li X, Wang X, Lu X, Cai X, Huang A, Luo G, You Q, Xiang H.. (2018) Design and synthesis of benzofuro[3,2-b]pyridin-2(1H)-one derivatives as anti-leukemia agents by inhibiting Btk and PI3Kδ.. Bioorg Med Chem, 26 (15): (4537-4543). [PMID:30077608]
147. Ge Y, Wang C, Song S, Huang J, Liu Z, Li Y, Meng Q, Zhang J, Yao J, Liu K, Ma X, Sun X.. (2018) Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma.. Eur J Med Chem, 143 (1847-1857). [PMID:29146136]
148. Pan Z, Chen Y, Liu J, Jiang Q, Yang S, Guo L, He G.. (2018) Design, synthesis, and biological evaluation of polo-like kinase 1/eukaryotic elongation factor 2 kinase (PLK1/EEF2K) dual inhibitors for regulating breast cancer cells apoptosis and autophagy.. Eur J Med Chem, 144 (517-528). [PMID:29288948]
149. Lovering F, Morgan P, Allais C, Aulabaugh A, Brodfuehrer J, Chang J, Coe J, Ding W, Dowty H, Fleming M, Frisbie R, Guzova J, Hepworth D, Jasti J, Kortum S, Kurumbail R, Mohan S, Papaioannou N, Strohbach JW, Vincent F, Lee K, Zapf CW.. (2018) Rational approach to highly potent and selective apoptosis signal-regulating kinase 1 (ASK1) inhibitors.. Eur J Med Chem, 145 (606-621). [PMID:29348070]
150. Jiang JK, Huang X, Shamim K, Patel PR, Lee A, Wang AQ, Nguyen K, Tawa G, Cuny GD, Yu PB, Zheng W, Xu X, Sanderson P, Huang W.. (2018) Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors.. Bioorg Med Chem Lett, 28 (20): (3356-3362). [PMID:30227946]
151. Wang B, Wu J, Wu Y, Chen C, Zou F, Wang A, Wu H, Hu Z, Jiang Z, Liu Q, Wang W, Zhang Y, Liu F, Zhao M, Hu J, Huang T, Ge J, Wang L, Ren T, Wang Y, Liu J, Liu Q.. (2018) Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor.. Eur J Med Chem, 158 (896-916). [PMID:30253346]
152. Caldwell R, Liu-Bujalski L, Qiu H, Mochalkin I, Jones R, Neagu C, Goutopoulos A, Grenningloh R, Johnson T, Sherer B, Gardberg A, Follis AV, Morandi F, Head J.. (2018) Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk.. Bioorg Med Chem Lett, 28 (21): (3419-3424). [PMID:30290988]
153. Dodo K, Kuboki E, Shimizu T, Imamura R, Magarisawa M, Takahashi M, Tokuhiro T, Yotsumoto S, Asano K, Nakao S, Terayama N, Suda T, Tanaka M, Sodeoka M.. (2019) Development of a Water-Soluble Indolylmaleimide Derivative IM-93 Showing Dual Inhibition of Ferroptosis and NETosis.. ACS Med Chem Lett, 10 (9): (1272-1278). [PMID:31531196]
154. Zhang Q, Hu X, Wan G, Wang J, Li L, Wu X, Liu Z, Yu L.. (2019) Discovery of 3-(((9H-purin-6-yl)amino)methyl)-4,6-dimethylpyridin-2(1H)-one derivatives as novel tubulin polymerization inhibitors for treatment of cancer.. Eur J Med Chem, 184 (111728-111728). [PMID:31610375]
155. Ran F, Liu Y, Zhang D, Liu M, Zhao G.. (2019) Discovery of novel pyrazole derivatives as potential anticancer agents in MCL.. Bioorg Med Chem Lett, 29 (9): (1060-1064). [PMID:30857748]
156. Rana S, Sonawane YA, Taylor MA, Kizhake S, Zahid M, Natarajan A.. (2018) Synthesis of aminopyrazole analogs and their evaluation as CDK inhibitors for cancer therapy.. Bioorg Med Chem Lett, 28 (23-24): (3736-3740). [PMID:30343954]
157. Narayan S, Ramisetti S, Jaiswal AS, Law BK, Singh-Pillay A, Singh P, Amin S, Sharma AK.. (2019) ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.. Eur J Med Chem, 161 (456-467). [PMID:30384048]
158. Osborne J, Birchall K, Tsagris DJ, Lewis SJ, Smiljanic-Hurley E, Taylor DL, Levy A, Alessi DR, McIver EG.. (2019) Discovery of potent and selective 5-azaindazole inhibitors of leucine-rich repeat kinase 2 (LRRK2) - Part 1.. Bioorg Med Chem Lett, 29 (4): (668-673). [PMID:30554956]
159. Wang Y, Dou X, Jiang L, Jin H, Zhang L, Zhang L, Liu Z.. (2019) Discovery of novel glycogen synthase kinase-3α inhibitors: Structure-based virtual screening, preliminary SAR and biological evaluation for treatment of acute myeloid leukemia.. Eur J Med Chem, 171 (221-234). [PMID:30925338]
160. Zhang C, Pei H, He J, Zhu J, Li W, Niu T, Xiang M, Chen L.. (2019) Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis.. Eur J Med Chem, 169 (121-143). [PMID:30875504]
161. Tang G, Liu L, Wang X, Pan Z.. (2019) Discovery of 7H-pyrrolo[2,3-d]pyrimidine derivatives as selective covalent irreversible inhibitors of interleukin-2-inducible T-cell kinase (Itk).. Eur J Med Chem, 173 (167-183). [PMID:30999237]
162. Zhai Z, Li R, Bai X, Ning X, Lin Z, Zhao X, Jin Y, Yin Y.. (2019) Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors.. Bioorg Med Chem, 27 (18): (4124-4142). [PMID:31395509]
163. Harris PA, Faucher N, George N, Eidam PM, King BW, White GV, Anderson NA, Bandyopadhyay D, Beal AM, Beneton V, Berger SB, Campobasso N, Campos S, Capriotti CA, Cox JA, Daugan A, Donche F, Fouchet MH, Finger JN, Geddes B, Gough PJ, Grondin P, Hoffman BL, Hoffman SJ, Hutchinson SE, Jeong JU, Jigorel E, Lamoureux P, Leister LK, Lich JD, Mahajan MK, Meslamani J, Mosley JE, Nagilla R, Nassau PM, Ng SL, Ouellette MT, Pasikanti KK, Potvain F, Reilly MA, Rivera EJ, Sautet S, Schaeffer MC, Sehon CA, Sun H, Thorpe JH, Totoritis RD, Ward P, Wellaway N, Wisnoski DD, Woolven JM, Bertin J, Marquis RW.. (2019) Discovery and Lead-Optimization of 4,5-Dihydropyrazoles as Mono-Kinase Selective, Orally Bioavailable and Efficacious Inhibitors of Receptor Interacting Protein 1 (RIP1) Kinase.. J Med Chem, 62 (10): (5096-5110). [PMID:31013427]
164. Heng H, Wang Z, Li H, Huang Y, Lan Q, Guo X, Zhang L, Zhi Y, Cai J, Qin T, Xiang L, Wang S, Chen Y, Lu T, Lu S.. (2019) Combining structure- and property-based optimization to identify selective FLT3-ITD inhibitors with good antitumor efficacy in AML cell inoculated mouse xenograft model.. Eur J Med Chem, 176 (248-267). [PMID:31103903]
165. Liu S, Jiang Y, Yan R, Li Z, Wan S, Zhang T, Wu X, Hou J, Zhu Z, Tian Y, Zhang J.. (2019) Design, synthesis and biological evaluations of 2-amino-4-(1-piperidine) pyridine derivatives as novel anti crizotinib-resistant ALK/ROS1 dual inhibitors.. Eur J Med Chem, 179 (358-375). [PMID:31260890]
166. Li X, Shi B, Teng Y, Cheng Y, Yang H, Li J, Wang L, He S, You Q, Xiang H.. (2019) Design, synthesis and biological evaluation of novel 2-phenyl pyrimidine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors.. Medchemcomm, 10 (2): (294-299). [PMID:30881616]
167. Zheng N, Hao Q, Lin K, Pan J, Li Y, Zhou W.. (2019) Synthesis and biological evaluation of novel 1-substituted 3-(3-phenoxyprop-1-yn-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amines as potent Bruton's tyrosine kinase (BTK) inhibitors.. Bioorg Med Chem Lett, 29 (2): (225-229). [PMID:30522954]
168. Wang X, Yu C, Wang C, Ma Y, Wang T, Li Y, Huang Z, Zhou M, Sun P, Zheng J, Yang S, Fan Y, Xiang R.. (2019) Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer.. Eur J Med Chem, 181 (111535-111535). [PMID:31376566]
169. Zhao L, Li Y, Wang Y, Qiao Z, Miao Z, Yang J, Huang L, Tian C, Li L, Chen D, Yang S.. (2019) Discovery of 4H-Chromen-4-one Derivatives as a New Class of Selective Rho Kinase (ROCK) Inhibitors, which Showed Potent Activity in ex Vivo Diabetic Retinopathy Models.. J Med Chem, 62 (23): (10691-10710). [PMID:31693351]
170. Jang J, Son JB, To C, Bahcall M, Kim SY, Kang SY, Mushajiang M, Lee Y, Jänne PA, Choi HG, Gray NS.. (2017) Discovery of a potent dual ALK and EGFR T790M inhibitor.. Eur J Med Chem, 136 (497-510). [PMID:28528303]
171. Wang Y, Li L, Fan J, Dai Y, Jiang A, Geng M, Ai J, Duan W.. (2018) Discovery of Potent Irreversible Pan-Fibroblast Growth Factor Receptor (FGFR) Inhibitors.. J Med Chem, 61 (20): (9085-9104). [PMID:29522671]
172. Bronner SM, Merrick KA, Murray J, Salphati L, Moffat JG, Pang J, Sneeringer CJ, Dompe N, Cyr P, Purkey H, Boenig GL, Li J, Kolesnikov A, Larouche-Gauthier R, Lai KW, Shen X, Aubert-Nicol S, Chen YC, Cheong J, Crawford JJ, Hafner M, Haghshenas P, Jakalian A, Leclerc JP, Lim NK, O'Brien T, Plise EG, Shalan H, Sturino C, Wai J, Xiao Y, Yin J, Zhao L, Gould S, Olivero A, Heffron TP.. (2019) Design of a brain-penetrant CDK4/6 inhibitor for glioblastoma.. Bioorg Med Chem Lett, 29 (16): (2294-2301). [PMID:31307887]
173. Oukoloff K, Coquelle N, Bartolini M, Naldi M, Le Guevel R, Bach S, Josselin B, Ruchaud S, Catto M, Pisani L, Denora N, Iacobazzi RM, Silman I, Sussman JL, Buron F, Colletier JP, Jean L, Routier S, Renard PY.. (2019) Design, biological evaluation and X-ray crystallography of nanomolar multifunctional ligands targeting simultaneously acetylcholinesterase and glycogen synthase kinase-3.. Eur J Med Chem, 168 (58-77). [PMID:30798053]
174. Andrews LD, Kane TR, Dozzo P, Haglund CM, Hilderbrandt DJ, Linsell MS, Machajewski T, McEnroe G, Serio AW, Wlasichuk KB, Neau DB, Pakhomova S, Waldrop GL, Sharp M, Pogliano J, Cirz RT, Cohen F.. (2019) Optimization and Mechanistic Characterization of Pyridopyrimidine Inhibitors of Bacterial Biotin Carboxylase.. J Med Chem, 62 (16): (7489-7505). [PMID:31306011]
175. Wang Q, Dai Y, Ji Y, Shi H, Guo Z, Chen D, Chen Y, Peng X, Gao Y, Wang X, Chen L, Jiang Y, Geng M, Shen J, Ai J, Xiong B.. (2019) Discovery and optimization of a series of 3-substituted indazole derivatives as multi-target kinase inhibitors for the treatment of lung squamous cell carcinoma.. Eur J Med Chem, 163 (671-689). [PMID:30572178]
176. Kang SJ, Lee JW, Chung SH, Jang SY, Choi J, Suh KH, Kim YH, Ham YJ, Min KH.. (2019) Synthesis and anti-tumor activity of imidazopyrazines as TAK1 inhibitors.. Eur J Med Chem, 163 (660-670). [PMID:30576901]
177. Guo Y, Liu Y, Hu N, Yu D, Zhou C, Shi G, Zhang B, Wei M, Liu J, Luo L, Tang Z, Song H, Guo Y, Liu X, Su D, Zhang S, Song X, Zhou X, Hong Y, Chen S, Cheng Z, Young S, Wei Q, Wang H, Wang Q, Lv L, Wang F, Xu H, Sun H, Xing H, Li N, Zhang W, Wang Z, Liu G, Sun Z, Zhou D, Li W, Liu L, Wang L, Wang Z.. (2019) Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.. J Med Chem, 62 (17): (7923-7940). [PMID:31381333]
178. Lin SY, Chang Hsu Y, Peng YH, Ke YY, Lin WH, Sun HY, Shiao HY, Kuo FM, Chen PY, Lien TW, Chen CH, Chu CY, Wang SY, Yeh KC, Chen CP, Hsu TA, Wu SY, Yeh TK, Chen CT, Hsieh HP.. (2019) Discovery of a Furanopyrimidine-Based Epidermal Growth Factor Receptor Inhibitor (DBPR112) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer.. J Med Chem, 62 (22): (10108-10123). [PMID:31560541]
179. Liu L, Li X, Cheng Y, Wang L, Yang H, Li J, He S, Shuangjie Wu, Yin Q, Xiang H.. (2019) Optimization of novel benzofuro[3,2-b]pyridin-2(1H)-one derivatives as dual inhibitors of BTK and PI3Kδ.. Eur J Med Chem, 164 (304-316). [PMID:30605829]
180. De Lucca GV, Shi Q, Liu Q, Batt DG, Beaudoin Bertrand M, Rampulla R, Mathur A, Discenza L, D'Arienzo C, Dai J, Obermeier M, Vickery R, Zhang Y, Yang Z, Marathe P, Tebben AJ, Muckelbauer JK, Chang CJ, Zhang H, Gillooly K, Taylor T, Pattoli MA, Skala S, Kukral DW, McIntyre KW, Salter-Cid L, Fura A, Burke JR, Barrish JC, Carter PH, Tino JA.. (2016) Small Molecule Reversible Inhibitors of Bruton's Tyrosine Kinase (BTK): Structure-Activity Relationships Leading to the Identification of 7-(2-Hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177).. J Med Chem, 59 (17): (7915-7935). [PMID:27531604]
181. Ren J, Shi W, Zhao D, Wang Q, Chang X, He X, Wang X, Gao Y, Lu P, Zhang X, Xu H, Zhang Y.. (2020) Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors.. Bioorg Med Chem, 28 (2): (115236-115236). [PMID:31843459]
182. Zhu Y, Zheng X, Wang C, Sun X, Sun H, Ma T, Li Y, Liu K, Chen L, Ma X.. (2020) Synthesis and biological activity of thieno[3,2-d]pyrimidines as potent JAK3 inhibitors for the treatment of idiopathic pulmonary fibrosis.. Bioorg Med Chem, 28 (2): (115254-115254). [PMID:31866272]
183. Crawford JJ, Lee W, Johnson AR, Delatorre KJ, Chen J, Eigenbrot C, Heidmann J, Kakiuchi-Kiyota S, Katewa A, Kiefer JR, Liu L, Lubach JW, Misner D, Purkey H, Reif K, Vogt J, Wong H, Yu C, Young WB.. (2020) Stereochemical Differences in Fluorocyclopropyl Amides Enable Tuning of Btk Inhibition and Off-Target Activity.. ACS Med Chem Lett, 11 (8): (1588-1597). [PMID:32832028]
184. Yuan X,Wu H,Bu H,Zheng P,Zhou J,Zhang H. (2019) Design, synthesis and biological evaluation of pyridone-aminal derivatives as MNK1/2 inhibitors.. Bioorg Med Chem, 27 (7.0): (1211-1225). [PMID:30824167]
185. Hamilton GL,Chen H,Deshmukh G,Eigenbrot C,Fong R,Johnson A,Kohli PB,Lupardus PJ,Liederer BM,Ramaswamy S,Wang H,Wang J,Xu Z,Zhu Y,Vucic D,Patel S. (2019) Potent and selective inhibitors of receptor-interacting protein kinase 1 that lack an aromatic back pocket group.. Bioorg Med Chem Lett, 29 (12.0): (1497-1501). [PMID:31000154]
186. Pulz R,Angst D,Dawson J,Gessier F,Gutmann S,Hersperger R,Hinniger A,Janser P,Koch G,Revesz L,Vulpetti A,Waelchli R,Zimmerlin A,Cenni B. (2019) Design of Potent and Selective Covalent Inhibitors of Bruton's Tyrosine Kinase Targeting an Inactive Conformation.. ACS Med Chem Lett, 10 (10.0): (1467-1472). [PMID:31620235]
187. Srivastava AS,Ko S,Watterson SH,Pattoli MA,Skala S,Cheng L,Obermeier MT,Vickery R,Discenza LN,D'Arienzo CJ,Gillooly KM,Taylor TL,Pulicicchio C,McIntyre KW,Yip S,Li P,Sun D,Wu DR,Dai J,Wang C,Zhang Y,Wang B,Pawluczyk J,Kempson J,Zhao R,Hou X,Rampulla R,Mathur A,Galella MA,Salter-Cid L,Barrish JC,Carter PH,Fura A,Burke JR,Tino JA. (2020) Driving Potency with Rotationally Stable Atropisomers: Discovery of Pyridopyrimidinedione-Carbazole Inhibitors of BTK.. ACS Med Chem Lett, 11 (11.0): (2195-2203). [PMID:33214829]
188. May-Dracka TL,Arduini R,Bertolotti-Ciarlet A,Bhisetti G,Brickelmaier M,Cahir-McFarland E,Enyedy I,Fontenot JD,Hesson T,Little K,Lyssikatos J,Marcotte D,McKee T,Murugan P,Patterson T,Peng H,Rushe M,Silvian L,Spilker K,Wu P,Xin Z,Burkly LC. (2018) Investigating small molecules to inhibit germinal center kinase-like kinase (GLK/MAP4K3) upstream of PKCθ phosphorylation: Potential therapy to modulate T cell dependent immunity.. Bioorg Med Chem Lett, 28 (10): (1964-1971). [PMID:29636220]
189. Shu L,Chen C,Huan X,Huang H,Wang M,Zhang J,Yan Y,Liu J,Zhang T,Zhang D. (2020) Design, synthesis, and pharmacological evaluation of 4- or 6-phenyl-pyrimidine derivatives as novel and selective Janus kinase 3 inhibitors.. Eur J Med Chem, 191 (112148-112148). [PMID:32097841]
190. Unzue, Andrea, Jessen-Trefzer, Claudia, Spiliotopoulos, Dimitrios, Gaudio, Eugenio, Tarantelli, Chiara, Dong, Jing, Zhao, Hongtao, Pachmayr, Johanna, Zahler, Stefan, Bernasconi, Elena, Sartori, Giulio, Cascione, Luciano, Bertoni, Francesco, Sledz, Pawel, Caflisch, Amedeo, Nevado, Cristina. (2020) Understanding the mechanism of action of pyrrolo[3,2-b]quinoxaline-derivatives as kinase inhibitors. RSC Med Chem, 11 (6): (665-675). [PMID:33479666]
191. Li,ZH.; Ma,JL.; Liu,GZ.; Zhang,XH.; Qin,TT.; Ren,WH.; Zhao,TQ.; Chen,XH.; Zhang,ZQ.. (2020) [1,2,3]Triazolo[4,5-d]pyrimidine derivatives incorporating (thio)urea moiety as a novel scaffold for LSD1 inhibitors.. Eur J Med Chem, 187 (111989-111989). [PMID:31881456]
192. Liu J,Guiadeen D,Krikorian A,Gao X,Wang J,Boga SB,Alhassan AB,Yu Y,Vaccaro H,Liu S,Yang C,Wu H,Cooper A,de Man J,Kaptein A,Maloney K,Hornak V,Gao YD,Fischmann TO,Raaijmakers H,Vu-Pham D,Presland J,Mansueto M,Xu Z,Leccese E,Zhang-Hoover J,Knemeyer I,Garlisi CG,Bays N,Stivers P,Brandish PE,Hicks A,Kim R,Kozlowski JA. (2016) Discovery of 8-Amino-imidazo[1,5-a]pyrazines as Reversible BTK Inhibitors for the Treatment of Rheumatoid Arthritis.. ACS Med Chem Lett, 7 (2.0): (198-203). [PMID:26985298]
193. He L,Pei H,Zhang C,Shao M,Li D,Tang M,Wang T,Chen X,Xiang M,Chen L. (2018) Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as selective Btk inhibitors with improved pharmacokinetic properties for the treatment of rheumatoid arthritis.. Eur J Med Chem, 145 (96-112). [PMID:29324347]
194. Ding X,Stasi LP,Ho MH,Zhao B,Wang H,Long K,Xu Q,Sang Y,Sun C,Hu H,Yu H,Wan Z,Wang L,Edge C,Liu Q,Li Y,Dong K,Guan X,Tattersall FD,Reith AD,Ren F. (2018) Discovery of 4-ethoxy-7H-pyrrolo[2,3-d]pyrimidin-2-amines as potent, selective and orally bioavailable LRRK2 inhibitors.. Bioorg Med Chem Lett, 28 (9.0): (1615-1620). [PMID:29588215]
195. Liu J,Guiadeen D,Krikorian A,Gao X,Wang J,Babu Boga S,Alhassan AB,Yu W,Selyutin O,Yu Y,Anand R,Xu J,Kelly J,Duffy JL,Liu S,Yang C,Wu H,Cai J,Bennett C,Maloney KM,Tyagarajan S,Gao YD,Fischmann TO,Presland J,Mansueto M,Xu Z,Leccese E,Zhang-Hoover J,Knemeyer I,Garlisi CG,Stivers P,Brandish PE,Hicks A,Kim R,Kozlowski JA. (2020) Potent, non-covalent reversible BTK inhibitors with 8-amino-imidazo[1,5-a]pyrazine core featuring 3-position bicyclic ring substitutes.. Bioorg Med Chem Lett, 30 (17): (127390-127390). [PMID:32738973]
196. Zhang X,Sheng X,Shen J,Zhang S,Sun W,Shen C,Li Y,Wang J,Lv H,Cui M,Zhu Y,Huang L,Hao D,Qi Z,Sun G,Mao W,Pan Y,Shen L,Li X,Hu G,Gong Z,Han S,Li J,Chen S,Tu R,Wang X,Wu C. (2020) Discovery and Evaluation of Pyrazolo[3,4-d]pyridazinone as a Potent and Orally Active Irreversible BTK Inhibitor.. ACS Med Chem Lett, 11 (10): (1863-1868). [PMID:33062165]
197. Yang J,Chen K,Zhang G,Yang QY,Li YS,Huang SZ,Wang YL,Yang W,Jiang XJ,Yan HX,Zhu JQ,Xiang R,Luo YF,Li WM,Wei YQ,Li LL,Yang SY. (2018) Structural optimization and structure-activity relationship studies of N-phenyl-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-4-amine derivatives as a new class of inhibitors of RET and its drug resistance mutants.. Eur J Med Chem, 143 (1148-1164). [PMID:29133048]
198. Teng Y,Lu X,Xiao M,Li Z,Zou Y,Ren S,Cheng Y,Luo G,Xiang H. (2020) Discovery of potent and highly selective covalent inhibitors of Bruton's tyrosine kinase bearing triazine scaffold.. Eur J Med Chem, 199 (112339-112339). [PMID:32402933]
199. Jorda R,Krajčovičová S,Králová P,Soural M,Kryštof V. (2020) Scaffold hopping of the SYK inhibitor entospletinib leads to broader targeting of the BCR signalosome.. Eur J Med Chem, 204 (112636-112636). [PMID:32731189]
200. Krajčovičová S, Jorda R, Vanda D, Soural M, Kryštof V.. (2021) 1,4,6-Trisubstituted imidazo[4,5-c]pyridines as inhibitors of Bruton's tyrosine kinase.. Eur J Med Chem, 211 (113094-113094). [PMID:33340912]
201. Liang X, Tang S, Liu X, Liu Y, Xu Q, Wang X, Saidahmatov A, Li C, Wang J, Zhou Y, Zhang Y, Geng M, Huang M, Liu H.. (2022) Discovery of Novel Pyrrolo[2,3-d]pyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors.. J Med Chem, 65 (2.0): (1243-1264). [PMID:33586434]
202. Oeltjen, J C JC and 6 more authors.. (1995) Sixty-nine kilobases of contiguous human genomic sequence containing the alpha-galactosidase A and Bruton's tyrosine kinase loci.. Mammalian genome : official journal of the International Mammalian Genome Society, [PMID:7626884]
203. Hagemann, T L TL, Rosen, F S FS and Kwan, S P SP.. (1995) Characterization of germline mutations of the gene encoding Bruton's tyrosine kinase in families with X-linked agammaglobulinemia.. Human mutation, [PMID:7627183]
204. Jin, H H and 9 more authors.. (1995) Identification of Btk mutations in 20 unrelated patients with X-linked agammaglobulinaemia (XLA).. Human molecular genetics, [PMID:7633420]
205. Gaspar, H B HB and 7 more authors.. (1995) Mutation analysis in Bruton's tyrosine kinase, the X-linked agammaglobulinaemia gene, including identification of an insertional hotspot.. Human molecular genetics, [PMID:7633429]
206. Vorechovský, I I and 8 more authors.. (1995) DNA-based mutation analysis of Bruton's tyrosine kinase gene in patients with X-linked agammaglobulinaemia.. Human molecular genetics, [PMID:7711734]
207. Vihinen, M M and 9 more authors.. (1994) Structural basis for chromosome X-linked agammaglobulinemia: a tyrosine kinase disease.. Proceedings of the National Academy of Sciences of the United States of America, (20): [PMID:7809124]
208. Vihinen, M M and 8 more authors.. (1995) Structural basis for pleckstrin homology domain mutations in X-linked agammaglobulinemia.. Biochemistry, (7): [PMID:7849006]
209. Conley, M E ME, Fitch-Hilgenberg, M E ME, Cleveland, J L JL, Parolini, O O and Rohrer, J J.. (1994) Screening of genomic DNA to identify mutations in the gene for Bruton's tyrosine kinase.. Human molecular genetics, [PMID:7849697]
210. Zhu, Q Q, Zhang, M M, Winkelstein, J J, Chen, S H SH and Ochs, H D HD.. (1994) Unique mutations of Bruton's tyrosine kinase in fourteen unrelated X-linked agammaglobulinemia families.. Human molecular genetics, [PMID:7849721]
211. Hagemann, T L TL, Chen, Y Y, Rosen, F S FS and Kwan, S P SP.. (1994) Genomic organization of the Btk gene and exon scanning for mutations in patients with X-linked agammaglobulinemia.. Human molecular genetics, [PMID:7880320]
212. Ohashi, Y Y, Tsuchiya, S S and Konno, T T.. (1995) A new point mutation involving a highly conserved leucine in the Btk SH2 domain in a family with X linked agammaglobulinaemia.. Journal of medical genetics, [PMID:7897635]
213. Rohrer, J J, Parolini, O O, Belmont, J W JW, Conley, M E ME and Parolino O [corrected to Parolini, O ] O].. (1994) The genomic structure of human BTK, the defective gene in X-linked agammaglobulinemia.. Immunogenetics, [PMID:7927535]
214. Duriez, B B and 5 more authors.. (1994) An exon-skipping mutation in the btk gene of a patient with X-linked agammaglobulinemia and isolated growth hormone deficiency.. FEBS letters, (13): [PMID:8013627]
215. Ohta, Y Y and 9 more authors.. (1994) Genomic organization and structure of Bruton agammaglobulinemia tyrosine kinase: localization of mutations associated with varied clinical presentations and course in X chromosome-linked agammaglobulinemia.. Proceedings of the National Academy of Sciences of the United States of America, (13): [PMID:8090769]
216. de Weers, M M, Mensink, R G RG, Kraakman, M E ME, Schuurman, R K RK and Hendriks, R W RW.. (1994) Mutation analysis of the Bruton's tyrosine kinase gene in X-linked agammaglobulinemia: identification of a mutation which affects the same codon as is altered in immunodeficient xid mice.. Human molecular genetics, [PMID:8162018]
217. Bradley, L A LA and 6 more authors.. (1994) Mutation detection in the X-linked agammaglobulinemia gene, BTK, using single strand conformation polymorphism analysis.. Human molecular genetics, [PMID:8162056]
218. Vetrie, D D and 9 more authors.. (1993) The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases.. Nature, (21): [PMID:8380905]
219. Tsukada, S S and 9 more authors.. (1993) Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia.. Cell, (29): [PMID:8425221]
220. Vihinen, M M and 6 more authors.. (1996) BTKbase, mutation database for X-linked agammaglobulinemia (XLA).. Nucleic acids research, (1): [PMID:8594569]
221. Park, H H and 8 more authors.. (1996) Regulation of Btk function by a major autophosphorylation site within the SH3 domain.. Immunity, [PMID:8630736]
222. Vorechovský, I I and 5 more authors.. (1995) Improved oligonucleotide primer set for molecular diagnosis of X-linked agammaglobulinaemia: predominance of amino acid substitutions in the catalytic domain of Bruton's tyrosine kinase.. Human molecular genetics, [PMID:8634718]
223. Hashimoto, S S and 16 more authors.. (1996) Identification of Bruton's tyrosine kinase (Btk) gene mutations and characterization of the derived proteins in 35 X-linked agammaglobulinemia families: a nationwide study of Btk deficiency in Japan.. Blood, (15): [PMID:8695804]
224. Schuster, V V, Seidenspinner, S S and Kreth, H W HW.. (1996) Detection of a novel mutation in the SRC homology domain 2 (SH2) of Bruton's tyrosine kinase and direct female carrier evaluation in a family with X-linked agammaglobulinemia.. American journal of medical genetics, (3): [PMID:8723128]
225. Kobayashi, S S and 7 more authors.. (1996) Mutations of the Btk gene in 12 unrelated families with X-linked agammaglobulinemia in Japan.. Human genetics, [PMID:8834236]
226. Yang, W W and Desiderio, S S.. (1997) BAP-135, a target for Bruton's tyrosine kinase in response to B cell receptor engagement.. Proceedings of the National Academy of Sciences of the United States of America, (21): [PMID:9012831]
227. Vihinen, M M and 13 more authors.. (1997) BTKbase, mutation database for X-linked agammaglobulinemia (XLA). Nucleic acids research, (1): [PMID:9016530]
228. Hyvönen, M M and Saraste, M M.. (1997) Structure of the PH domain and Btk motif from Bruton's tyrosine kinase: molecular explanations for X-linked agammaglobulinaemia.. The EMBO journal, (16): [PMID:9218782]
229. Saha, B K BK, Curtis, S K SK, Vogler, L B LB and Vihinen, M M.. (1997) Molecular and structural characterization of five novel mutations in the Bruton's tyrosine kinase gene from patients with X-linked agammaglobulinemia.. Molecular medicine (Cambridge, Mass.), [PMID:9260159]
230. Vihinen, M M and 10 more authors.. (1997) Missense mutations affecting a conserved cysteine pair in the TH domain of Btk.. FEBS letters, (18): [PMID:9280283]
231. Holinski-Feder, E E and 10 more authors.. (1998) Mutation screening of the BTK gene in 56 families with X-linked agammaglobulinemia (XLA): 47 unique mutations without correlation to clinical course.. Pediatrics, [PMID:9445504]
232. Hansson, H H and 6 more authors.. (1998) Solution structure of the SH3 domain from Bruton's tyrosine kinase.. Biochemistry, (3): [PMID:9485443]
233. Conley, M E ME, Mathias, D D, Treadaway, J J, Minegishi, Y Y and Rohrer, J J.. (1998) Mutations in btk in patients with presumed X-linked agammaglobulinemia.. American journal of human genetics, [PMID:9545398]
234. Matsushita, M M and 12 more authors.. (1998) Identification and characterization of a novel SH3-domain binding protein, Sab, which preferentially associates with Bruton's tyrosine kinase (BtK).. Biochemical and biophysical research communications, (17): [PMID:9571151]
235. and Uckun, F M FM.. (1998) Bruton's tyrosine kinase (BTK) as a dual-function regulator of apoptosis.. Biochemical pharmacology, (15): [PMID:9751072]
236. Baraldi, E E and 8 more authors.. (1999) Structure of the PH domain from Bruton's tyrosine kinase in complex with inositol 1,3,4,5-tetrakisphosphate.. Structure (London, England : 1993), (15): [PMID:10196129]
237. Várnai, P P, Rother, K I KI and Balla, T T.. (1999) Phosphatidylinositol 3-kinase-dependent membrane association of the Bruton's tyrosine kinase pleckstrin homology domain visualized in single living cells.. The Journal of biological chemistry, (16): [PMID:10196179]
238. Vihinen, M M and 7 more authors.. (1999) Mutations of the human BTK gene coding for bruton tyrosine kinase in X-linked agammaglobulinemia.. Human mutation, [PMID:10220140]
239. Yamadori, T T and 7 more authors.. (1999) Bruton's tyrosine kinase activity is negatively regulated by Sab, the Btk-SH3 domain-binding protein.. Proceedings of the National Academy of Sciences of the United States of America, (25): [PMID:10339589]
240. Orlandi, P P and 8 more authors.. (2000) Identification of nine novel mutations in the Bruton's tyrosine kinase gene in X-linked agammaglobulinaemia patients.. Human mutation, [PMID:10612838]
241. Curtis, S K SK, Hebert, M D MD and Saha, B K BK.. (2000) Twin carriers of X-linked agammaglobulinemia (XLA) due to germline mutation in the Btk gene.. American journal of medical genetics, (31): [PMID:10678660]
242. Tzeng, S R SR, Lou, Y C YC, Pai, M T MT, Jain, M L ML and Cheng, J W JW.. (2000) Solution structure of the human BTK SH3 domain complexed with a proline-rich peptide from p120cbl.. Journal of biomolecular NMR, [PMID:10826882]
243. Mohamed, A J AJ and 5 more authors.. (2000) Nucleocytoplasmic shuttling of Bruton's tyrosine kinase.. The Journal of biological chemistry, (22): [PMID:11016936]
244. Mao, C C, Zhou, M M and Uckun, F M FM.. (2001) Crystal structure of Bruton's tyrosine kinase domain suggests a novel pathway for activation and provides insights into the molecular basis of X-linked agammaglobulinemia.. The Journal of biological chemistry, (2): [PMID:11527964]
245. Liu, W W and 7 more authors.. (2001) Direct inhibition of Bruton's tyrosine kinase by IBtk, a Btk-binding protein.. Nature immunology, [PMID:11577348]
246. Kang, S W SW and 11 more authors.. (2001) PKCbeta modulates antigen receptor signaling via regulation of Btk membrane localization.. The EMBO journal, (15): [PMID:11598012]
247. Rodriguez, R R and 9 more authors.. (2001) Tyrosine residues in phospholipase Cgamma 2 essential for the enzyme function in B-cell signaling.. The Journal of biological chemistry, (21): [PMID:11606584]
248. Vargas, Leonardo L and 6 more authors.. (2002) Functional interaction of caveolin-1 with Bruton's tyrosine kinase and Bmx.. The Journal of biological chemistry, (15): [PMID:11751885]
249. Nore, Beston F BF and 9 more authors.. (2003) Identification of phosphorylation sites within the SH3 domains of Tec family tyrosine kinases.. Biochimica et biophysica acta, (21): [PMID:12573241]
250. Guo, Shuling S and 7 more authors.. (2004) A phosphorylation site in Bruton's tyrosine kinase selectively regulates B cell calcium signaling efficiency by altering phospholipase C-gamma activation.. Proceedings of the National Academy of Sciences of the United States of America, (28): [PMID:15375214]
251. Ross, Mark T MT and 281 more authors.. (2005) The DNA sequence of the human X chromosome.. Nature, (17): [PMID:15772651]
252. Mansell, Ashley A and 9 more authors.. (2006) Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation.. Nature immunology, [PMID:16415872]
253. Yu, Liang L and 6 more authors.. (2006) Regulation of Bruton tyrosine kinase by the peptidylprolyl isomerase Pin1.. The Journal of biological chemistry, (30): [PMID:16644721]
254. Rajaiya, Jaya J and 5 more authors.. (2006) Induction of immunoglobulin heavy-chain transcription through the transcription factor Bright requires TFII-I.. Molecular and cellular biology, [PMID:16738337]
255. Huang, Kuo-Chun KC, Cheng, Hsi-Tsung HT, Pai, Ming-Tao MT, Tzeng, Shiou-Ru SR and Cheng, Jya-Wei JW.. (2006) Solution structure and phosphopeptide binding of the SH2 domain from the human Bruton's tyrosine kinase.. Journal of biomolecular NMR, [PMID:16969585]
256. Mohamed, Abdalla J AJ and 10 more authors.. (2009) Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain.. Immunological reviews, [PMID:19290921]
257. Oppermann, Felix S FS and 7 more authors.. (2009) Large-scale proteomics analysis of the human kinome.. Molecular & cellular proteomics : MCP, [PMID:19369195]
258. Voss, Matthias M, Lettau, Marcus M and Janssen, Ottmar O.. (2009) Identification of SH3 domain interaction partners of human FasL (CD178) by phage display screening.. BMC immunology, (6): [PMID:19807924]
259. Kuglstatter, Andreas A and 9 more authors.. (2011) Insights into the conformational flexibility of Bruton's tyrosine kinase from multiple ligand complex structures.. Protein science : a publication of the Protein Society, [PMID:21280133]
260. Zhou, Houjiang H and 6 more authors.. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome.. Journal of proteome research, (4): [PMID:23186163]
261. Eifert, Cheryl C and 6 more authors.. (2013) A novel isoform of the B cell tyrosine kinase BTK protects breast cancer cells from apoptosis.. Genes, chromosomes & cancer, [PMID:23913792]
262. Furman, Richard R and 14 more authors.. (2014) Ibrutinib resistance in chronic lymphocytic leukemia.. The New England journal of medicine, (12): [PMID:24869597]
263. Woyach, Jennifer A JA and 24 more authors.. (2014) Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.. The New England journal of medicine, (12): [PMID:24869598]
264. Cheng, S S and 5 more authors.. (2015) Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors.. Leukemia, [PMID:25189416]
265. Kim, Esther S ES and Dhillon, Sohita S.. (2015) Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia.. Drugs, [PMID:25802231]
266. Qi, Wei W and 39 more authors.. (2017) An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.. Nature chemical biology, [PMID:28135235]
267. Tarantelli, Chiara C and 11 more authors.. (2019) The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents.. Haematologica, [PMID:30679329]
268. Tam, Constantine Si Lun CSL and 20 more authors.. (2019) Phase 1 study of selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL.. Blood, (24): [PMID:31340982]
269. Castillo, Jorge J and Treon, Steven P.. (2019) What is new in the treatment of Waldenstrom macroglobulinemia?. Leukemia, [PMID:31591468]
270. Castillo, Jorge J and Treon, Steven P.. (2020) Management of Waldenström macroglobulinemia in 2020.. Hematology. American Society of Hematology. Education Program, (4): [PMID:33275726]

Solution Calculators

Molarity Calculator

Determine the necessary mass, volume, or concentration for preparing a solution.

Dilution Calculator

Determine the dilution needed to prepare a stock solution.

SKU	Size	Availability	Price
Ab091828-10μl	10μl	In stock	$66.90
Ab091828-50μl	50μl	In stock	$199.90
Ab091828-100μl	100μl	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$309.90
Ab091828-1ml	1ml	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$2,699.90

Recombinant BTK Antibody - Primary antibody, specific to BTK, Rabbit IgG